Introduction
tumor, cancer death, HCC, malignant tumor, ALBI
HEPATOCELLULAR CARCINOMA, MALIGNANT TUMOR, TUMOR
Hepatocellular carcinoma (HCC), the fourth leading cause of cancer death, is a common malignant tumor with more than 840,000 new cases worldwide each year (Bray et al. Radiomics has emerged as a new field in tumor treatment research in recent years (Gillies et al. To our knowledge, the value of an MRI-based radiomics combined with ALBI scores in predicting the HCC’s therapeutic response after HAIC has not yet been investigated. Thus, the purpose of the current study was to construct and validate a novel nomogram based on a pretherapeutic MRI-based radiomics score combined with an ALBI score to predict the therapeutic response of unresectable HCC after HAIC.